How can we discover developable antibody-based biotherapeutics?
Antibody-based biotherapeutics have emerged as a successful class of pharmaceuticals
despite significant challenges and risks to their discovery and development. This review …
despite significant challenges and risks to their discovery and development. This review …
Contextualising the developability risk of antibodies with lambda light chains using enhanced therapeutic antibody profiling
Antibodies with lambda light chains (λ-antibodies) are generally considered to be less
developable than those with kappa light chains (κ-antibodies). Though this hypothesis has …
developable than those with kappa light chains (κ-antibodies). Though this hypothesis has …
Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability
Designing effective monoclonal antibody (mAb) therapeutics faces a multi-parameter
optimization challenge known as “developability”, which reflects an antibody's ability to …
optimization challenge known as “developability”, which reflects an antibody's ability to …
In Silico Approaches to Deliver Better Antibodies by Design: The Past, the Present and the Future
The recognition of the importance of drug-like properties beyond potency to reduce clinical
attrition of biologics has driven significant progress in the development of in vitro and in …
attrition of biologics has driven significant progress in the development of in vitro and in …
Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies
Bispecific antibodies (BsAbs) capable of recognizing two distinct epitopes or antigens offer
promising therapeutic options for various diseases by targeting multiple pathways. The …
promising therapeutic options for various diseases by targeting multiple pathways. The …
Predicting deamidation and isomerization sites in therapeutic antibodies using structure-based in silico approaches
Asparagine (Asn) deamidation and aspartic acid (Asp) isomerization are common
degradation pathways that affect the stability of therapeutic antibodies. These modifications …
degradation pathways that affect the stability of therapeutic antibodies. These modifications …
Biophysical cartography of the native and human-engineered antibody landscapes quantifies the plasticity of antibody developability
Designing effective monoclonal antibody (mAb) therapeutics face a significant challenge
known as" developability", which reflects an antibody's ability to progress through …
known as" developability", which reflects an antibody's ability to progress through …
Cartography of the developability landscapes of native and human-engineered antibodies
Design: ing effective monoclonal antibody (mAb) therapeutics face a significant challenge
known as “developability”, which reflects an antibody's ability to progress through …
known as “developability”, which reflects an antibody's ability to progress through …